- Medisca and EUROAPI have formed a strategic partnership to expand access to APIs for pharmaceutical compounding in North America, including exclusive supply arrangements for selected APIs.
- The companies plan to expand the API offering over time and explore additional markets, customer initiatives, training, commercial activities and peptide collaboration.
Medisca has formed a strategic partnership with EUROAPI to expand access to active pharmaceutical ingredients (APIs) for the North American pharmaceutical compounding market and establish a framework for broader international growth and peptide collaboration.
Under the partnership, Medisca will become EUROAPI’s first strategic distribution partner focused on bringing its European-manufactured APIs to the North American compounding market. The agreement includes exclusive supply arrangements for selected APIs, with the companies planning to add new APIs over time and evaluate opportunities in additional markets.
The collaboration is intended to connect EUROAPI’s manufacturing and technical expertise with Medisca’s direct insight into the needs of pharmaceutical compounders. EUROAPI will provide available technical and regulatory information related to the APIs, while Medisca will support the products through its quality infrastructure, documentation and customer-facing systems.
“This partnership marks an important milestone in the growth of Medisca. EUROAPI brings deep manufacturing and technical expertise, with a strong focus on quality, green chemistry and sustainability.”
Peng Li, Chief Business Officer at Medisca
The companies also intend to collaborate on customer initiatives, training and commercial activities. The partnership will explore opportunities to expand the offering across markets and advance collaboration in peptides, while supporting Medisca’s approach to responsible sourcing and its broader social impact commitments.
